Alamar Biosciences Raises 2026 Revenue Outlook To $121 Million–$123 Million As President Tod White Plans To Retire

Third-quarter sales rose 68% to $33.5 million, with biopharma the largest customer group for the first time, as the net loss widened.

Share
Alamar Biosciences Raises 2026 Revenue Outlook To $121 Million–$123 Million As President Tod White Plans To Retire

Alamar Biosciences, which makes instruments and test kits that measure proteins in blood, raised its 2026 revenue forecast to $121 million to $123 million after third-quarter revenue climbed 68%. In an 8-K, the company also said President Tod White will retire at year-end.

Guidance up, biopharma in front

The new range replaces a prior outlook of $116 million to $120 million. The company said the midpoint implies 64% growth over 2025.

Third-quarter revenue was $33.5 million, against $19.9 million a year earlier. Consumables rose 79% to $17.8 million, instruments 50% to $8.5 million and services 69% to $7.2 million.

Founder, CEO and Chair Yuling Luo said biopharma customers were the largest part of revenue for the first time. He said the UK Biobank selection and a new GSK collaboration show institutions and drug developers are choosing its NULISA technology "to reach the low-abundance proteome at scale." UK Biobank picked Alamar to profile 80,000 samples, and the GSK study covers 60,000 samples.

Margins improve, losses deepen

Gross margin rose to 61.5% from 59.7%, which the company credited to lower instrument costs, higher consumable prices, better service margins and product mix.

Operating expenses jumped 81% to $35.8 million, on headcount, infrastructure, research supplies and public-company costs. The operating loss widened to $15.1 million from $7.9 million, including $3.9 million of stock-based pay. Net loss was $13.3 million, against $8.0 million, or $0.19 per share versus $0.69 on a much larger share count (69,106,367 weighted-average shares versus 11,599,353).

Cash, equivalents, short-term investments and restricted cash totaled $231.5 million as of September 30.

White's exit at year-end

White told the company on October 30 that he will retire as president effective December 31, then consult from January 1, 2027 through June 30, 2027. He joined as chief financial officer and chief business officer in March 2021 and became president in October 2025, the company said, leading finance, scaling operations and helping guide the IPO.

Luo called him "an outstanding partner and leader during a pivotal period for Alamar."

Alamar sells the ARGO HT System, a research-use benchtop instrument, plus assays and software, to academic, biopharma and contract research customers. Management holds a call at 4:30 p.m. ET on Tuesday on the results.

White's retirement takes effect December 31, and his consulting term runs through June 30, 2027.

Sources